NKGen Biotech (NYSE:NKGN – Get Free Report) is one of 280 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare NKGen Biotech to similar companies based on the strength of its risk, earnings, institutional ownership, valuation, dividends, analyst recommendations and profitability.
Volatility and Risk
NKGen Biotech has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, NKGen Biotech’s competitors have a beta of 1.08, indicating that their average stock price is 8% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for NKGen Biotech and its competitors, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
NKGen Biotech | 0 | 0 | 0 | 0 | N/A |
NKGen Biotech Competitors | 1582 | 4717 | 12221 | 236 | 2.59 |
Earnings & Valuation
This table compares NKGen Biotech and its competitors gross revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
NKGen Biotech | $80,000.00 | -$82.94 million | -0.08 |
NKGen Biotech Competitors | $569.56 million | -$31.32 million | -42.97 |
NKGen Biotech’s competitors have higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares NKGen Biotech and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
NKGen Biotech | N/A | N/A | -479.36% |
NKGen Biotech Competitors | -5,175.29% | -173.59% | -43.23% |
Insider and Institutional Ownership
76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 50.2% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 20.0% of NKGen Biotech shares are held by company insiders. Comparatively, 16.2% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
NKGen Biotech Company Profile
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
Receive News & Ratings for NKGen Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NKGen Biotech and related companies with MarketBeat.com's FREE daily email newsletter.